Factors linked to heart problems, such as high blood pressure, diabetes and bad cholesterol levels, can start years, ...
Despite advancements in treatment and prevention, patients with established atherosclerotic cardiovascular disease (ASCVD) still have particularly high risk of having another heart attack, stroke, or ...
Once-weekly semaglutide 2.4 mg reduced the risk for major adverse cardiovascular events among adults with overweight or obesity who were at risk for atherosclerotic cardiovascular disease, according ...
Asianet Newsable on MSN
New Drug Cuts Bad Cholesterol by Nearly 60% in First-Year Trials
Discover Enlicitide, a new daily pill for genetic high cholesterol (HeFH). A recent trial shows it lowers bad LDL cholesterol ...
Any aspirin use linked to lower hazards of MI, ischemic stroke, with greater benefit in high-frequency use group.
News-Medical.Net on MSN
New data supports earlier use of evolocumab in high-risk diabetes
Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major ...
The Family Heart Foundation, a non-profit research and advocacy organization to lead research and education, focusing on genetic dyslipidemias, has launched the Lp(a) AW(a)RE initiative to engage key ...
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback